Semaglutide, a glucagon-like peptide-1 receptor agonist, was primarily a drug in diabetes therapy that was subsequently FDA approved for long-term weight management, cardiovascular risk reduction and nonalcoholic fatty liver disease in patients with HIV.
The FDA permits the compounding of Semaglutide due to shortages but only if the product is compounded by pharmacies following the regulations contained in Section 503A of the Federal Food, Drug and Cosmetic Act (FD&C Act).In this article we will cover how to obtain Compounded Semaglutide (CS), its potential side effects, who is eligible for using CS for weight loss and what are unauthorized forms of CS.